Noetik

Approach

Noetik partnered with Thermal to position its contrarian approach – training AI on human biology rather than animal models that fail 90% of the time – at the forefront of precision oncology. Together, we:

• • Coordinated high-impact partnership announcements: Executed launch communications for Noetik’s first pharma collaboration with Agenus, a milestone validation of its virtual cell platform for predicting clinical response to immunotherapy combinations. Managed strategic messaging to position the partnership as proof of Noetik’s differentiated approach—deploying foundation models directly on clinical trial data.
  • Secured marquee media placements: Secured a Washington Post Live appearance on the “Chasing Cancer” series to discuss how AI is shaping the future of cancer care. Positioned Noetik for inclusion in flagship industry features profiling the leading approaches to virtual cell development.
  • Amplified scientific leadership through conference communications: Coordinated media outreach around Noetik’s presentations at AACR 2025 and SITC 2025, positioning the company’s OCTO-virtual cell and Perturb-map platforms as first-in-class discovery engines for precision oncology.
  • Built executive visibility through speaking and panels: Secured speaking engagements on biopharma executive panels including the Galien Forum in New York, elevating Noetik’s profile among pharma decision-makers and investors.

Impact

Through our partnership, Noetik has:

• • Secured first pharma partnership: Announced collaboration with Agenus to develop AI-enabled biomarkers for their lead immunotherapy combination, deploying Noetik’s virtual cell models on active clinical program data for the first time—validating the platform’s commercial potential.
  • Secured tier-one industry coverage including exclusive Endpoints News features on key business development milestones, reinforcing Formation’s positioning as the ideal partner for companies with promising assets facing capital or time constraints.
  • Built sustained visibility with key audiences through strategic awards recognition including Endpoints 11, establishing Formation Bio as one of biotech’s most exciting and promising startups.
  • Created scalable communications infrastructure including comprehensive PR roadmaps, messaging architecture, and media relations frameworks supporting Formation’s growth toward a portfolio of drug assets.